Research Paper Volume 15, Issue 24 pp 15213—15227
A potential therapeutic approach for gastric cancer: inhibition of LACTB transcript 1
- 1 Center of Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
- 2 Department of Basic Clinical Laboratory and Hematology, School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, China
- 3 Department of Gastrointestinal Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, China
Received: July 6, 2023 Accepted: November 3, 2023 Published: December 26, 2023
https://doi.org/10.18632/aging.205345How to Cite
Copyright: © 2023 Nie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: This study sought to investigate the role of LACTB transcript 1 in regulating adaptive immune resistance and stemness in gastric cancer and its potential as a therapeutic target for precision medicine.
Methods: Bioinformatics analysis and RT-qPCR were used to analyze the expression level of LACTB and its transcripts in gastric cancer cells. The effects of LACTB transcript 1 on adaptive immune resistance and stemness were evaluated using in vitro cell experiments and western blotting experiments.
Results: Our study findings revealed that LACTB transcript 1 modulated adaptive immune resistance and inhibited the stemness of gastric cancer cells. Knocking down the expression level of LACTB transcript 1 activated autophagy and inhibited EMT. As expected, overexpression of LACTB transcript 1 yielded the opposite findings. The expression level of LACTB transcript 1 in the peripheral blood of gastric cancer patients was consistent with the bioinformatics analysis, suggesting its potential as a biomarker of gastric cancer.
Conclusions: LACTB transcript 1 is a promising therapeutic target for precision medicine in gastric cancer by modulating immune evasion mechanisms and stemness. These findings provide insights into leveraging long non-coding RNAs (lncRNAs) in immunotherapy, radiotherapy, and chemotherapy to enhance cancer therapy efficacy, particularly in the context of targeting tumor heterogeneity and stemness.